By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
Currency | US Dollars |
Share Price | $ 134.15 |
Change Today | $ 1.02 |
% Change | 0.77 % |
52 Week High | $236.72 |
52 Week Low | $118.84 |
Volume | 1,049,625 |
Shares Issued | 145.80m |
Market Cap | $19,559m |
RiskGrade | 259 |
Strong Buy | 6 |
Buy | 8 |
Neutral | 21 |
Sell | 0 |
Strong Sell | 0 |
Total | 35 |
Time | Volume / Share Price |
16:00 | 210,281 @ $134.15 |
15:59 | 100 @ $134.15 |
15:59 | 100 @ $134.15 |
15:59 | 100 @ $134.15 |
15:59 | 100 @ $134.15 |
You are here: research